- Home
- CHNR vs QNRX Comparison
CHNR vs QNRX Comparison
Compare CHNR & QNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHNR
- QNRX
- Stock Information
- Founded
- CHNR N/A
- QNRX 2018
- Country
- CHNR China
- QNRX United States
- Employees
- CHNR N/A
- QNRX N/A
- Industry
- CHNR Precious Metals
- QNRX Medical/Dental Instruments
- Sector
- CHNR Basic Materials
- QNRX Health Care
- Exchange
- CHNR Nasdaq
- QNRX Nasdaq
- Market Cap
- CHNR 5.3M
- QNRX 4.8M
- IPO Year
- CHNR 1995
- QNRX N/A
- Fundamental
- Price
- CHNR $4.79
- QNRX $10.08
- Analyst Decision
- CHNR
- QNRX
- Analyst Count
- CHNR 0
- QNRX 0
- Target Price
- CHNR N/A
- QNRX N/A
- AVG Volume (30 Days)
- CHNR 994.4K
- QNRX 840.7K
- Earning Date
- CHNR 12-12-2025
- QNRX 11-06-2025
- Dividend Yield
- CHNR N/A
- QNRX N/A
- EPS Growth
- CHNR N/A
- QNRX N/A
- EPS
- CHNR N/A
- QNRX N/A
- Revenue
- CHNR N/A
- QNRX N/A
- Revenue This Year
- CHNR N/A
- QNRX N/A
- Revenue Next Year
- CHNR N/A
- QNRX N/A
- P/E Ratio
- CHNR N/A
- QNRX N/A
- Revenue Growth
- CHNR N/A
- QNRX N/A
- 52 Week Low
- CHNR $3.16
- QNRX $5.01
- 52 Week High
- CHNR $8.20
- QNRX $48.30
- Technical
- Relative Strength Index (RSI)
- CHNR 39.93
- QNRX 44.74
- Support Level
- CHNR $5.00
- QNRX $12.55
- Resistance Level
- CHNR $5.79
- QNRX $13.55
- Average True Range (ATR)
- CHNR 0.61
- QNRX 1.86
- MACD
- CHNR -0.22
- QNRX -0.63
- Stochastic Oscillator
- CHNR 10.34
- QNRX 3.20
About CHNR China Natural Resources Inc.
China Natural Resources Inc is engaged in exploration for lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and exploration of attractive opportunities in other sectors. The company has a single operating segment: exploration and mining.
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.